CGM Interoperability (iCGM) Patent Landscape 2026
The iCGM interoperability patent space is tightly concentrated, with Dexcom and Medtronic MiniMed together accounting for the dominant share of a 47-family corpus anchored overwhelmingly in the United States. Annual filing volume peaked in 2021 and has since eased, signalling a field moving from rapid build-out toward selective deepening in informatics and AI-driven control.
Dexcom leads a highly concentrated, two-tier iCGM field
Dexcom holds the top position with 17 patent families, followed by Medtronic MiniMed at 13. Together with Nudge BG (8) and TT1 Prod (7), the top four applicants account for the vast majority of the corpus, making this one of the more concentrated medical-device interoperability spaces in the dataset.
The top five filers hold 91% of the combined total across the hundred largest filers — a concentration level that leaves limited open terrain between the two established leaders and a small group of challengers. The gap between the second tier (Nudge BG, TT1 Prod) and the remaining applicants is significant.
| # | Applicant | Patent families | Share |
|---|---|---|---|
| 1 | Dexcom Inc | 17 | |
| 2 | Medtronic MiniMed Inc | 13 | |
| 3 | Nudge BG Inc | 8 | |
| 4 | TT1 Prod Inc | 7 | |
| 5 | Indian Institute of Technology Madras | 3 | |
| 6 | TT1 Inc | 2 | |
| 7 | Parul University (Parul Institute of Technology) | 1 | |
| 8 | PARUL UNIV (PARUL INST OF MEDICAL SCI & RES) | 1 | |
| 9 | UXN Ltd | 1 |
Dexcom’s position in healthcare informatics and data-processing IP, combined with Medtronic MiniMed’s emphasis on diagnostic and AI-model patents, suggests the two leaders are building complementary but distinct moats — one around data infrastructure, the other around clinical-grade sensing and predictive algorithms.
Filings from the most recent 18–24 months are subject to publication lag and likely under-represent actual activity; late-period counts should be treated as provisional. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
A 2021 filing peak followed by easing volume; informatics dominates the technology mix
The annual trend and technology-composition charts together reveal a field that surged in 2021 and has since moderated, while its technical centre of gravity sits firmly in healthcare informatics and clinical diagnostics rather than pure connectivity.
Annual filing trend
Filing volume rose from 7 families in 2017 to a peak of 13 in 2021, then stepped down through 2022 (9) and fell further in 2023–2025. The lifecycle evidence confirms annual volume has eased from the 2021 peak; figures for 2024–2026 are subject to publication lag and should not be read as the terminal trajectory.
↗ Hover for values · click a bar to ask EurekaTechnology composition
G16H (Healthcare informatics) and A61B (Diagnosis & surgery) are the two leading IPC branches, reflecting the regulatory and clinical demands of iCGM certification. G06F (digital data processing), G06N (AI/ML models), and G05B (control systems) each represent smaller but strategically significant clusters, pointing toward algorithm-heavy innovation as a secondary front.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Implantable continuous glucose monitor device
A continuous glucose monitor (CGM) sensor includes a glucose oxidation electrode and a counter electrode, and does not include a glucose-specific enzyme. The glucose oxidation electrode includes a nanoporous layer comprising metal nanoparticles. The CGM sensor generates an electrical signal indicative glucose oxidation in a liquid containing glucose, which… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Distributed system architecture for continuous glu… | 34 |
| 2 | Micro models and layered prediction models for est… | 8 |
| 3 | Systems and methods for CGM-based bolus calculator… | 8 |
| 4 | Distributed system architecture for continuous glu… | 8 |
| 5 | Machine learning models for detecting outliers and… | 7 |
| 6 | Micro models and layered prediction models for est… | 6 |
| 7 | Burden-free blood glucose management for insulin-r… | 5 |
| 8 | Biomarker monitoring fitness system | 4 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the iCGM structure means for R&D investment decisions
The combination of high concentration, a post-peak lifecycle, and an informatics-heavy technology mix shapes where meaningful R&D differentiation is still feasible.
Post-peak field with selective residual activity
The lifecycle stage is classified as Decline, driven by annual filings easing back from the 2021 peak. The multi-year window still shows a corpus assembled largely after 2019, meaning the body of prior art is recent and dense rather than aged. New entrants face a well-stocked prior-art landscape; incremental claims require precise differentiation.
Life-cycle: DeclineTwo incumbents control the core; challenger tier is thin
The top five filers hold 91% of the combined total across the hundred largest filers, with Dexcom (17 families) and Medtronic MiniMed (13 families) defining the front tier. The second tier — Nudge BG (8) and TT1 Prod (7) — is present but narrow. Any new entrant must either out-manoeuvre two well-resourced incumbents or focus on the technical adjacencies they have not yet claimed.
High concentrationNo recorded co-applicant activity in this corpus
Evidence shows no collaboration pairs among the active filers. The absence of co-filing suggests the leading applicants treat iCGM IP as proprietary and competitive rather than pre-competitive. Academic applicants (IIT Madras, Parul University) appear to file independently, offering a potential partnership channel that has not yet been exploited.
No co-filing detectedUS-centric filing with limited international reach
The United States accounts for 34 of the recorded patent filings, far ahead of Canada (5), India (4), and PCT (4). Europe (EPO) holds only 3 and China 1, indicating that iCGM interoperability IP protection outside North America is sparse. For applicants seeking to commercialise in European or Asian markets, the international filing gap is an observable structural feature of this corpus.
US-dominantGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
Co-filing pairs, ranked by the number of jointly-filed patent families.
Dexcom emphasises informatics infrastructure; Medtronic MiniMed leads on diagnostic and AI IP
The two front-tier players occupy distinct but overlapping technical niches within iCGM interoperability, with Nudge BG emerging as the most active challenger.
Dexcom
Dexcom holds 17 patent families — the largest position in this corpus — concentrated in G16H 40 (healthcare informatics management) and G06F 21 (data processing security and access control). This portfolio architecture suggests a strategic focus on the system and data-layer requirements of iCGM certification. Momentum is classified as a new entrant in the recent window, indicating recent filings represent a fresh cohort rather than a continuation of a prior multi-year run.
families: 17Medtronic MiniMed
Medtronic MiniMed holds 13 patent families, with a strong emphasis on A61B 5 (diagnostic sensing) and G06N 20 (machine-learning models), alongside G16H 40. This positions the company as the leader in sensor-algorithm integration within the iCGM space. Like Dexcom, its recent filing activity is classified as a new entrant cohort in the momentum analysis. Nudge BG (8 families, focused on A61M 5 fluid-delivery devices and G05B 23 control systems) is the most distinct challenger by technology emphasis.
families: 13| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Dexcom Inc | 2 | ▲ new entrant |
| Medtronic MiniMed Inc | 5 | ▲ new entrant |
| Nudge BG Inc | 4 | ▲ new entrant |
| Indian Institute of Technology Madras | 3 | ▲ new entrant |
| Parul University (Parul Institute of Technology) | 1 | ▲ new entrant |
| PARUL UNIV (PARUL INST OF MEDICAL SCI & RES) | 1 | ▲ new entrant |
Under-served adjacent branches worth monitoring in iCGM
Several IPC branches appear at low absolute counts relative to the dominant G16H and A61B clusters; they are observations of relative sparsity and should be evaluated for technical fit and entry path before treating them as investment targets.
G06N · AI and machine-learning models
With 9 patent records and a 7% share of the IPC distribution, G06N is the sparsest branch among those with plausible iCGM relevance. Medtronic MiniMed holds the most focused position here (G06N 20 appears prominently in its portfolio), but the branch as a whole is underdeveloped relative to the clinical ambition of iCGM. Glucose-trajectory prediction, outlier detection, and personalised dosing algorithms all map naturally to this branch, and the top-cited patent titles referencing ‘micro models and layered prediction models’ confirm technical demand. An entrant with differentiated ML methodology could file into a relatively open space while addressing a clinically validated need.
Search this in Eureka →H04L / H04W · Digital and wireless communication networks
H04L (7 records, 5% share) and H04W (3 records, 2% share) together represent the connectivity and interoperability stack that the iCGM regulatory framework explicitly requires — yet combined they total only 10 records. The regulatory mandate for iCGM devices to function with compatible insulin delivery systems implies persistent technical demand for secure, low-latency data exchange protocols. Neither Dexcom nor Medtronic MiniMed appears to have staked a dominant position in this branch, making it an adjacent area where communications specialists or device integration firms could establish a foothold.
Search this in Eureka →How leading applicants differ across iCGM technology routes
Route coverage across the main technology branches in the current evidence set.
| Player | G16H 40 · Healthcare informatics | A61B 5 · Diagnosis & surgery | A61M 5 · Devices for body fluids | G16H 20 · Healthcare informatics | G16H 50 · Healthcare informatics |
|---|---|---|---|---|---|
| Dexcom Inc | Strong · 17 | Moderate · 6 | Moderate · 7 | Moderate · 8 | Strong · 10 |
| Nudge BG Inc | Strong · 8 | Absent | Strong · 8 | Strong · 8 | Absent |
| Medtronic MiniMed Inc | Strong · 7 | Strong · 10 | Absent | Absent | Strong · 7 |
| Indian Institute of Technology Madras | Moderate · 1 | Strong · 3 | Strong · 3 | Absent | Moderate · 1 |
| TT1 Prod Inc | Absent | Strong · 7 | Absent | Absent | Absent |
| Parul University (Parul Institute of Medical Sciences and Research) | Strong · 1 | Strong · 1 | Absent | Strong · 1 | Absent |
| Parul University (Parul Institute of Technology) | Strong · 1 | Strong · 1 | Absent | Strong · 1 | Absent |
Frequently asked questions
The corpus contains 47 patent families in scope, filed across multiple jurisdictions with the United States as the dominant filing office.
Dexcom holds the largest position with 17 patent families, followed by Medtronic MiniMed with 13 patent families. Together they define the front tier of this field.
Annual filing volume peaked in 2021 at 13 families and has eased since. The lifecycle is classified as Decline based on this post-peak trajectory; recent-year figures (2024–2026) remain subject to publication lag.
G16H (Healthcare informatics) and A61B (Diagnosis and surgery) are the two leading IPC branches, reflecting the clinical and regulatory demands of iCGM certification. AI/ML (G06N) and control systems (G05B) are secondary but strategically relevant clusters.
No co-applicant activity is recorded in this corpus. All active filers — including academic institutions such as IIT Madras and Parul University — appear to file independently, leaving cross-sector partnership as an unexploited channel.
The United States dominates with 34 recorded filings. Canada (5), India (4), and PCT (4) are the next largest, while Europe (EPO) holds only 3 and China 1. International protection outside North America is sparse relative to the global market for iCGM-compatible devices.
Ready to map your own iCGM patent landscape?
Join 18,000+ innovators using PatSnap Eureka to map any technology landscape: search 2B+ patents and papers, surface key assignees, and generate a report like this in minutes.
Disclaimer. This page is generated from PatSnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. PatSnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.